CO2MO
EU CTIS ID: 2025-520913-29-00
What this study is testing
To evaluate clinical performance of IOpener-melanoma in patients where standard of care treatment selection is based on IOpener-melanoma test result
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Unresectable stage III or stage IV cutaneous melanoma for whom treatment with immune checkpoint inhibitors (ICIs) is considered by the treating physician.
- Inclusion of patients with brain metastases is permitted if the metastases are asymptomatic or have been treated.
- Anticipated life expectancy exceeding 3 months.
- Aged 18 years or older and written informed consent for participation in the study.
You likely can't join if
- Prior treatment for irresectable stage III or stage IV melanoma with BRAF/MEK inhibitors or immunotherapy
- Serum LDH >2x ULN.
- Presence of symptomatic brain metastases
- WHO performance score > 2.
- (Neo)adjuvant treatment with anti-PD1 immunotherapy received within the last 6 months.
- Patients undergoing other experimental treatments or therapies that may interfere with the immunotherapy's mechanism of action or assessment of its effects might be excluded.
See the full eligibility criteria
- Unresectable stage III or stage IV cutaneous melanoma for whom treatment with immune checkpoint inhibitors (ICIs) is considered by the treating physician.
- Inclusion of patients with brain metastases is permitted if the metastases are asymptomatic or have been treated.
- Anticipated life expectancy exceeding 3 months.
- Aged 18 years or older and written informed consent for participation in the study.
- Prior treatment for irresectable stage III or stage IV melanoma with BRAF/MEK inhibitors or immunotherapy
- Serum LDH >2x ULN.
- Presence of symptomatic brain metastases
- WHO performance score > 2.
- (Neo)adjuvant treatment with anti-PD1 immunotherapy received within the last 6 months.
- Patients undergoing other experimental treatments or therapies that may interfere with the immunotherapy's mechanism of action or assessment of its effects might be excluded.
- Pregnant, lactating, or breast-feeding women.
- Presence of any medical or other conditiën that in the opinion of the investigator(s) would preclude the participation in a clinical study.
- Unwillingness or inability to comply with study and follow-up procedures
The study team makes the final eligibility decision.
Where it's taking place
- Netherlands
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Netherlands. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from EU CTIS. The study team decides eligibility, and your own doctor gives medical advice.